Benzodiazepine and Z-Drug Prescribing Policy
Privacy Policy
Benzodiazepines and Z-Drug Prescribing Policy
At Present Psychiatry, patient safety and evidence-based care are our highest priorities. To ensure responsible prescribing practices and to reduce the risk of dependence, misuse, and adverse health outcomes, the following policy applies to all patients:

Benzodiazepines
:-1 We do not prescribe benzodiazepines (such as Xanax, Ativan, Klonopin, or Valium) for the ongoing treatment of anxiety or depression.
:-2 Benzodiazepines may only be considered in short-term, time-limited situations (e.g., acute crisis stabilization, medical procedures, or when clinically appropriate and supported by guidelines).
:-3 Long-term management of anxiety and depression will focus on first-line treatments, including psychotherapy, SSRIs, SNRIs, and other evidence-based non-benzodiazepine medications.
:-4 Patients requesting benzodiazepines for chronic use will be referred to appropriate non-benzodiazepine treatment options.
Z-Drugs (e.g., Zolpidem, Ambien, Lunesta)
:-1 We do not prescribe zolpidem or other “Z-drugs” for the treatment of sleep disorders.
:-2 Management of insomnia will emphasize behavioral interventions (CBT-I), sleep hygiene, and non-habit-forming alternatives when medication is appropriate.
Patient Education
:-1 All patients will be educated about the risks of dependence, tolerance, withdrawal, and cognitive impairment associated with benzodiazepines and Z-drugs.
:-2 Alternative treatment plans will be developed collaboratively with each patient to address their symptoms safely and effectively.
Exceptions
:-1 Exceptions to this policy may be made in rare, clinically justified circumstances.
:-2 Exceptions are strictly limited to one-time, short prescriptions intended only to bridge the gap and prevent withdrawal symptoms when clinically necessary.
:-3 Any exception will require clear documentation of the rationale, risk-benefit assessment, and a time-limited treatment plan.